BiotechTube

Placebo + AG-348

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 34/100
34
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pyruvate Kinase Deficiency

Conditions

Pyruvate Kinase Deficiency, Anemia, Hemolytic

Trial Timeline

Aug 9, 2018 → Oct 9, 2020

NCT ID
NCT03548220

About Placebo + AG-348

Placebo + AG-348 is a phase 3 stage product being developed by Agios Pharmaceuticals for Pyruvate Kinase Deficiency. The current trial status is completed. This product is registered under clinical trial identifier NCT03548220. Target conditions include Pyruvate Kinase Deficiency, Anemia, Hemolytic.

What happened to similar drugs?

1 of 5 similar drugs in Pyruvate Kinase Deficiency were approved

Approved (1) Terminated (0) Active (4)
🔄Mitapivat + Mitapivat-matching placeboAgios PharmaceuticalsPhase 3
🔄Mitapivat + Mitapivat-matching placeboAgios PharmaceuticalsPhase 3
🔄MitapivatAgios PharmaceuticalsPhase 3
✅MitapivatAgios PharmaceuticalsApproved
🔄AG-348Agios PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03548220Phase 3Completed

Competing Products

9 competing products in Pyruvate Kinase Deficiency

See all competitors
ProductCompanyStageHype Score
TriheptanoinUltragenyx PharmaceuticalPhase 1
30
Mitapivat + Mitapivat-matching placeboAgios PharmaceuticalsPhase 3
38
Mitapivat + Mitapivat-matching placeboAgios PharmaceuticalsPhase 3
38
MitapivatAgios PharmaceuticalsPhase 3
34
MitapivatAgios PharmaceuticalsApproved
44
AG-348Agios PharmaceuticalsPhase 3
34
AG-348Agios PharmaceuticalsPhase 2
29
RP-L301Rocket PharmaceuticalsPhase 1
19
RP-L301Rocket PharmaceuticalsPhase 2
32